The global situation of MDR-TB

Tuberculosis

Volumn 83, Issue 1-3, 2003, Pages 44-51

  Espinal, Marcos A ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; ISONIAZID; RIFAMPICIN;

ACCURACY; BIOAVAILABILITY; CHINA; CONFERENCE PAPER; CONFIDENCE INTERVAL; DEVELOPED COUNTRY; DRUG SENSITIVITY; ESTONIA; GEOGRAPHY; HEALTH SURVEY; HUMAN; LATVIA; MATHEMATICAL MODEL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; RELIABILITY; RUSSIAN FEDERATION; TUBERCULOSIS; WORLD HEALTH ORGANIZATION;

EID: 0037841362     PISSN: 14729792     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1472-9792(02)00058-6     Document Type: Conference Paper

References (70)

1. Snider DE, La Montagne JR. The neglected global tuberculosis problem: a report of the 1992 world congress on tuberculosis. J Infect Dis 1994;169:1189-96.
2. Crofton J, Mitchison DA. Streptomycin resistance in pulmonary tuberculosis. Br Med J 1948;2:1009-15.
3. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999;3:S231-79.
4. Canetti G, Froman S, Grosset J, et al. Mycobacteria: laboratory methods for testing drug sensitivity and resistance. Bull World Health Organ 1963;29:565-78.
5. Selroos O. Drub susceptibility in pulmonary tuberculosis. In: XVIIIe Conference Internationale de la Tuberculose. Munich: Excerpta Medica International Congress Series 5-9, 1965. No. 96. p. 87.
6. Nitti V. Gli aspetti epidemiologici della resistenza micobatterica. II problema della resistenza primitiva. Atti del XVIII Congresso Italiano di Tisologia, vol. 2, 1966:p. 210.
7. Miller AB, Tall R, Fox W, Lefford MJ, Mitchison DA. Primary drug resistance in pulmonary tuberculosis in Great Britain: second national survey. Tubercle 1966;47:92-107.
8. Armstrong AR. The prevalence in Canada of drug resistant tubercle bacilli in newly discovered untreated patients with tuberculosis. Can Med Assoc J 1966;94:420-5.
9. Howells G. Primary drug resistance in Australia in 1968. Tubercle 1969;50:344-9.
10. Tuberculosis Research Committee. Primary drug resistance to the major anti-tuberculosis drugs in Japan. Tubercle 1970;51:152-71.
11. Canetti G, Gay PH, Le Lirzin M. Trends in the prevalence of primary drug resistance in pulmonary tuberculosis in France from 1961 to 1979: a national survey. Tubercle 1972;53:57-83.
12. United States Public Health Service Cooperative Investigation. Prevalence of drug resistance in previously untreated patients. Am Rev Respir Dis 1964;89:327-31
13. Hobby GL, Johnson PM, Lenert TF, et al. A continuing study of primary drug resistance in tuberculosis in a veteran population within the United States. I. Am Rev Respir Dis 1964;89:337-41.
14. Hobby GL, Johnson PM, Crawford-Gaglioardi L, Boytar V, Johnson GE. Primary drug resistance: a continuing study of primary drug resistance in tuberculosis in a veteran population within the United States. V. September 1963 to September 1965. Am Rev Respir Dis 1966;94:703-8.
15. Hobby GL, Johnson PM, Boytar-Papirnyik V. Primary drug resistance: a continuing study of drug resistance in tuberculosis in a veteran population within the United States. VII. September 1965 to September 1969. Am Rev Respir Dis 1970;102:347-55.
16. Hobby GL, Johnson PM, Boytar-Papirnyik V. Primary drug resistance: a continuing study of drug resistance in tuberculosis in a veteran population within the United States. IX. September 1969 to September 1970. Am Rev Respir Dis 1971;103:842-4.
17. Doster B, Caras GJ, Snider DE. A continuing survey of primary drug resistance in tuberculosis, 1961 to 1968. Am Rev Respir Dis 1976;113:419-25.
18. Hong Kong/British Medical Research Council Drug Resistance Survey. Drug-resistance in patients with pulmonary tuberculosis presenting at chest clinics in Hong Kong. Tubercle 1964;45:77-95.
19. East African/British Medical Research Council Kenya Tuberculosis Survey. Tuberculosis in Kenya: a national sampling survey of drug resistance and other factors. Tubercle 1968;49:136-69.
20. Indian Council of Medical Research. Prevalence of drug resistance in patients with pulmonary tuberculosis presenting for the first time with symptoms at chest clinics in India. I. Findings in urban clinics among patients giving no history of previous chemotherapy. Indian J Med Res 1968;56:1617-30.
21. Furesz S, Timball MT. The antibacterial activity of rifamycins. Chemotherapia 1963;7:200.
22. Fox W. The current status of short-course chemotherapy. Bull Int Union Tuberc 1978;53:268-80.
23. Keers RY. Pulmonary tuberculosis: a journey down the centuries. London: Balliere-Tindall, 1978.
24. Institute of Medicine. Ending neglect: the elimination of tuberculosis in the United States. Washington, DC: National Academic Press, 2000.
25. Robert J, Trystram D, Truffot-Pernot C, Carbonnelle B. Grosset, for the AZAY Mycobacteria Study Group. Surveillance of Mycobacterium tuberculosis drug resistance in France, 1995-1997. Int J Tuberc Lung Dis 2000;4:665-72.
26. Kopanoff DE, Kilburn JO, Glassroth JL, Snider DE, Farer LS, Good RC. A continuing survey of tuberculosis primary drug resistance in the United States: march 1975 to november 1977. Am Rev Respir Dis 1978;118:835-42.
27. Centers for Disease Control. Primary resistance to antituberculosis drugs - United States. Morb Mortal Wkly Rep 1980;29:345-46.
28. Centers for Disease Control. Primary resistance to antituberculosis drugs - United States. Morb Mortal Wkly Rep 1983;32:521-23.
29. Snider DE, Cauthen GM, Farer LS, et al. Drug resistant tuberculosis. Am Rev Respir Dis 1991;144:732.
30. Raviglione MC, Pio A. Evolution of WHO policies for tuberculosis control, 1948-2001. Lancet 2002;359:775-80.
31. Kleeberg HH, Olivier MS. A world atlas of initial drug resistance, 2nd ed. Pretoria, South Africa: Tuberculosis Research Institute of the South African Medical Research Council, 1984. p 1-34.
32. Cohn DL, Bustreo F, Raviglione MC. Drug-resistant tuberculosis: review of the worldwide situation and the WHO/IUATLD global surveillance project. Clin Infect Dis 1997;24:S121-30.
33. Snider Jr DE, Raviglione M, Kochi A. Global burden of tuberculosis. In: Bloom BR, editor. Tuberculosis: pathogenesis, protection, and control. Washington, DC: ASM Press, 1994. p. 3-11.
34. Raviglione MC, Snider Jr DE, Kochi A. Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic. JAMA 1995;273:220-6.
35. Edlin BR, Tokars JI, Grieco MH, et al. An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N Engl J Med 1992;326:1514-21.
36. Beck-Sague C, Dooley SW, Hutton MD, et al. Hospital outbreak of multidrug-resistant Mycobacterium tuberculosis infections: factors in transmission to staff and HIV-infected patients. JAMA 1992;268:1280-6.
37. Fischl MA, Uttamchandani RB, Daikos GL, et al. An outbreak of tuberculosis caused by multiple-drug-resistant tubercle bacilli among patients with HIV infection. Ann Intern Med 1992;117:177-83.
38. C.M. Michaud, C.J.L. Murray. Aid flows to the health sector in developing countries: a detailed analysis, 1972-1990. Health Transition Working Paper Series Number 93.08. Cambridge MA: Harvard Center for Population and Development Studies, 1991.
39. WHO/IUATLD. Guidelines for surveillance of drug resistance in tuberculosis. Int J Tuberc Lung Dis 1998;2:71-89.
40. World Health Organization. Anti-tuberculosis drug resistance in the world. WHO/TB/97.229. Geneva: WHO, 1997.
41. Pablos-Mendez A, Raviglione MC, Laszlo A, et al. Global surveillance for antituberculosis-drug resistance, 1994-1997. N Engl J Med 1998;338:1641-9.
42. World Health Organization. Anti-tuberculosis drug resistance in the world: prevalence and trends. Report No. 2. WHO/CDS/TB/2000.278. Geneva: WHO, 2000
43. Espinal MA, Laszlo A, Simonsen L, et al. Global trends in resistance to antituberculosis drugs. N Engl J Med 2001;344:1294-303.
44. Dye C, Williams BG, Espinal MA, Raviglione MC. Erasing the world's slow stain: strategies to beat multidrug-resistant tuberculosis. Science 2002;295:2042-6.
45. National Tuberculosis Programme. Tuberculosis in Latvia 1991-2000. Riga, 2001. p. 21-23.
46. Robert J, Trystram D, Pernot-Truffot C, Jarlier V. Surveillance de la tuberculose à bacilles multirésistants en France en 1998. Bull Epidémiol Hebdo 2002;16-17:71-2.
47. Thomsen VØ, Bauer J, Lillebaek T, Glismann S. Results from 8 yrs of susceptibility testing of clinical Mycobacterium tuberculosis isolates in Denmark. Eur Respir J 2000;15:203-8.
48. Moore M, McCray E, Onorato IM. The epidemiology of multidrug-resistant tuberculosis in the United States and other established market economies. In: Bastian I, Portaels F, editors. Multidrug-resistant tuberculosis. Dordrecht, The Netherlands: Kluwer Academic Publishers, 2000. p. 17-28.
49. Djuretic T, Herbert J, Drobniewski F, et al. Antibiotic resistant tuberculosis in the United Kingdom: 1993-1999. Thorax 2002;57:477-82.
50. Centers for Disease Control. Reported tuberculosis in the United States 2000. Atlanta, GA: US Department of Health and Human Services, CDC, August 2001.
51. Dye C, Espinal MA, Watt CJ, Mbiaga C, Williams BG. Worldwide incidence of multidrug-resistant tuberculosis. J Infect Dis 2002;185:1197-202.
52. Espinal MA, Kim SJ, Surarez PG, et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcome in 6 countries. JAMA 2000;283:2537-45.
53. Van Soolingen D. Molecular epidemiology of tuberculosis and other mycobacterial infections: main methodologies and achievements. J Intern Med 2001;249:1-26.
54. Bifani PJ, Mathema B, Kurepina NE, Kreiswirth B. Global dissemination of the Mycobacterium tuberculosis W-Beijing family strains. Trends Microbiol 2002;10:45-52.
55. Glynn JR, Whiteley J, Bifani PJ, Kremer K, van Soolingen D. Worldwide occurrence of Beijing/W strains of Mycobacterium tuberculosis: a systematic review. Emerg Infect Dis 2001;8:843-9.
56. Van Soolingen D, Borgdorff MW, de Hass PE, et al. Molecular epidemiology of tuberculosis in the Netherlands: a nation-wide study from 1993 through 1997. J Infect Dis 1999;180:726-36.
57. Garcia-Garcia M, Ponce de Leon A, Jimenez-Corona M, et al. Clinical consequences and transmissibility of drug-resistant tuberculosis in Southern Mexico. Arch Intern Med 2000;160:630-6.
58. Godfrey-Faucett P, Sonnenberg P, Shearer SC, et al. Tuberculosis control and molecular epidemiology in a South African gold-mining community. Lancet 2000;356:1066-71.
59. Texeira L, Perkins MD, Johnson JL, et al. Infection and disease among household contacts of patients with multi-drug-resistant tuberculosis. Int J Tuberc Lung Dis 2001;5:321-8.
60. Krunner A, Hoffner SE, Sillastu H, et al. Spread of drug-resistant pulmonary tuberculosis in Estonia. J Clin Microbiol 2001;39:3339-45.
61. Bifani PJ, Plikaytis BB, Kapur V, et al. Origin and interstate spread of a New York City multidrug-resistant Mycobacterium tuberculosis clone family. JAMA 1996;275:452-7.
62. Diaz R, Kremer K, de Hass PE, et al. Molecular epidemiology of tuberculosis in Cuba outside of Havana, July 1994-June 1995: utility of spoligotyping versus IS6110 restriction fragment length polymorphism. Int J Tuberc Lung Dis 1998;2:743-50.
63. Anh DD, Borgdorff M, Van LN, et al. Mycobacterium tuberculosis Beijing genotype emerging in Vietnam. Emerg Infect Dis 2000;6:302-5.
64. Zhang M, Gong J, Yang Z, Samten B, Cave MD, Barnes PF. Enhanced capacity of a widespread strain of Mycobacterium tuberculosis to grow in human macrophages. J Infect Dis 1999;79:367-70.
65. Kam KM, Yip CW. Surveillance of Mycobacterium tuberculosis drug resistance in Hong Kong, 1986-1999, after the implementation of directly observed treatment. Int J Tuberc Lung Dis 2001;5:815-23.
66. Kam KM, Yip CW, Tse LW, et al. Trends in multidrug-resistant Mycobacterium tuberculosis in relation to sputum smear positivity in Hong Kong, 1989-1999. Clin Infect Dis 2002;34:324-9.
67. Hong YP, Kim SJ, Bai JY, Lew WJ, Lee EG. Twenty-year trend of chronic excretors of tubercle bacilli based on the nationwide tuberculosis prevalence surveys in Korea, 1975-1995. Int J Tuberc Lung Dis 2000;10:911-9.
68. Dye C, Espinal M. Will tuberculosis become resistant to all antibiotics? Proc R Soc Lond B 2001;268:45-52.
69. Blower SM, Gerberding JLG. Understanding, predicting and controlling the emergence of drug-resistant tuberculosis: a theoretical framework. J Mol Med 1998;76:624-36.
70. Suarez PG, Floyd K, Portocarrero J, et al. Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in peru. Lancet 2001;359:1980-9.